Quantifying the effect of IV contrast media on integrated PET/CT: clinical evaluation.
暂无分享,去创建一个
Tinsu Pan | Osama Mawlawi | T. Pan | R. Munden | O. Mawlawi | D. Podoloff | J. Erasmus | H. Macapinlac | Jeremy J Erasmus | Reginald F Munden | Homer A Macapinlac | M. Chasen | Amy E Knight | Donald A Podoloff | Marvin Chasen | Amy Knight
[1] Imran Zoberi,et al. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Gerald Antoch,et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. , 2002, AJR. American journal of roentgenology.
[3] Jeffrey A. Fessler,et al. 3D PET reconstruction with FORE and WLS-OS-EM , 2002, 2002 IEEE Nuclear Science Symposium Conference Record.
[4] T. A. Smith,et al. FDG uptake, tumour characteristics and response to therapy: A review , 1998, Nuclear medicine communications.
[5] J. Padilla,et al. Surgical results and prognostic factors in early non-small cell lung cancer. , 1997, The Annals of thoracic surgery.
[6] P A Salvadori,et al. Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. , 2000, Clinical breast cancer.
[7] P. Dupont,et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] David W Townsend,et al. PET/CT today and tomorrow. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[9] D W. Townsend,et al. Combined PET/CT Imaging in Oncology. Impact on Patient Management. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[10] Paul Kinahan,et al. Attenuation correction for a combined 3D PET/CT scanner. , 1998, Medical physics.
[11] Richard L Wahl,et al. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography-clinical use, interpretation methods, diagnostic improvements. , 2003, Seminars in nuclear medicine.
[12] D. Visvikis,et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET , 2003, European Journal of Nuclear Medicine and Molecular Imaging.
[13] M. Schwaiger,et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] G. Peters,et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[15] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] C. Bokemeyer,et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Thomas Beyer,et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. , 2003, Radiology.
[18] M. Baccarani,et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients , 2004, British Journal of Cancer.
[19] G. Cook,et al. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. , 2004, Seminars in nuclear medicine.
[20] M C Gilardi,et al. PET/CT in diagnostic oncology. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....
[21] Mithat Gonen,et al. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[22] N. Altorki,et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. , 2004, The Annals of thoracic surgery.
[23] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] G. V. von Schulthess,et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. , 2003, The New England journal of medicine.
[25] Thomas Beyer,et al. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[26] M. Schwaiger,et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] M. Schwaiger,et al. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[28] F. Burgener,et al. Contrast enhancement of focal hepatic lesions in CT: effect of size and histology. , 1983, AJR. American journal of roentgenology.
[29] G. Perlmutter,et al. Oral contrast agents in CT of the abdomen. , 1984, Radiology.
[30] R L Wahl,et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] K. Herholz,et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.
[32] V. Bettinardi,et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study , 2004, European Journal of Nuclear Medicine and Molecular Imaging.
[33] E. Pauwels,et al. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology , 2001, Journal of Cancer Research and Clinical Oncology.
[34] Gerald Antoch,et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[35] E. Rota Kops,et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[36] Yuji Nakamoto,et al. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. , 2003, Radiology.